Solid Biosciences Inc.

Solid Biosciences Inc.

SLDBNYSE / NASDAQHealthcareSmall cap

$6.25-$0.19 (-3.0%)

Last close · Data as of Nov 20, 2026

Market cap
$712.8M
P/E
-4.1x
EV / EBITDA
-3.8x
Revenue
$0.00
ROCE
-90.0%

+40.1% over the last year

Solid Biosciences Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.3%
3M
-31.3%
6M
-3.4%
1Y
+40.1%
5Y
-79.1%

52-week range

Day change -$0.19 (-3.0%) from $6.44 to $6.25 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SLDB, bought on each weekday since 2021.

News & filings

What Solid Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 174 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 6.14 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.

Read moreShow less

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Sector
Healthcare
Shares outstanding
79.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$712.8M
P/E
-4.1x
P/B
4.0x
EV / EBITDA
-3.8x
52-week high
$11.15
52-week low
$4.46

Profitability

ROE
-96.8%
ROCE
-90.0%
ROIC
-100.2%
ROA
-75.0%

Growth

Revenue
$0.00
Net profit growth, 1Y
39.8%
Free cash flow
-$157.4M

Solvency

Current ratio
6.14
Debt / Equity
0.12
Debt / Assets
0.09
CFO / Net profit
0.90
Cash / Market cap
8.4%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Solid Biosciences Inc. revenue and net profit by fiscal year
Solid Biosciences Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$8.1M-$86.0M
FY2023$0.00-$96.0M
FY2024$0.00-$124.7M
FY2025$0.00-$174.3M

Cash flows

FY2025: -$156.3M from operations, -$157.4M free after investment (dashed).

Solid Biosciences Inc. operating and free cash flow by fiscal year
Solid Biosciences Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$98.0M-$101.0M
FY2023-$94.2M-$95.7M
FY2024-$100.0M-$100.7M
FY2025-$156.3M-$157.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$177.6M
Net profit
-$174.3M
Cash from operations
-$156.3M
Free cash flow
-$157.4M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$177.6M-$174.3M-$157.4M-96.8%—+39.8%

Monthly returns

Month-by-month returns of SLDB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$232.5M
Liabilities$52.5M
Equity$180.0M
Paid-in capital$1.1B
Retained earnings-$957.8M

Market cap against peers

8 peers: same sector, nearest by size.

  1. EVMN$745.2M
  2. Solid Biosciences Inc. (this company)$712.8M
  3. CBLL$711.4M

Peers map

Healthcare companies placed by value, growth and quality; SLDB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. EVMN54.1x
  2. CBLL7.8x

Not shown (no positive earnings and no EV / Sales): Solid Biosciences Inc., Omeros Corporation, Bright Minds Biosciences Inc., Allogene Therapeutics, Inc., Aura Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Solid Biosciences Inc.SLDBthis company$712.8M-4.1x4.0x-96.8%-3.8x
EVMNEVMN$745.2M-10.8x3.6x-33.5%-8.8x
Omeros CorporationOMER$741.8M-221.4x-6.1x2.8%-8.0x
HealthStream, Inc.HSTM$738.9M40.3x2.1x5.2%11.3x
Bright Minds Biosciences Inc.DRUG$731.0M-59.8x8.9x-14.9%-46.8x
CBLLCBLL$711.4M-13.3x4.6x-34.4%-13.8x
Enhabit, Inc.EHAB$706.9M-153.7x1.3x-0.9%20.1x
Allogene Therapeutics, Inc.ALLO$704.1M-3.7x2.4x-65.3%-4.1x
Aura Biosciences, Inc.AURA$703.0M-6.6x5.1x-77.6%-5.9x
Peer median—-12.1x3.0x-24.2%-6.9x

Year-to-date ROI

SLDB since 1 January, against earlier years.

Historical volatility

SLDB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Solid Biosciences Inc. operating margin by fiscal year
Solid Biosciences Inc. operating margin by fiscal year
DateOperating margin
FY2022-1227.1%
FY2023—
FY2024—
FY2025—
LineFY2025
Operating expensesOperating Expense$179.2M
Research and developmentResearch And Development$140.3M
Total expensesTotal Expenses$179.2M
Pretax incomePretax Income-$174.3M

Learn while you research

Academy chapters picked for Solid Biosciences Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →